9SO.F Solasia Pharma K.K

Healthcare Pharmaceuticals Frankfurt Exchange
0.1160 EUR
Close of Nov 12, 2026
0.0935 0.2000
Market cap
EUR 31.7M
P/E
-
P/B
3.86x
ROE
-79.7%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 9SO.F undervalued?

Graham number

The Graham number of Solasia Pharma K.K cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Solasia Pharma K.K fundamental analysis

No fundamental analysis for Solasia Pharma K.K yet.

Solasia Pharma K.K stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Solasia Pharma K.K

Solasia Pharma K.K. develops, markets, imports, and exports pharmaceutical products and medical devices in Japan, China, South Korea, and internationally. The company offers Episil (SP-03), an oral liquid for oral mucositis/stomatitis; DARVIAS (SP-02), an antineoplastic agent injection for relapsed or refractory peripheral T-cell lymphoma; and Sancuso (SP-01) for chemotherapy-induced nausea and vomiting. It also develops SP-04, which is in a preclinical trial for chemotherap…

Full company profile